PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8412748-1	1993	We evaluated the hypothesis that sodium phenylbutyrate-induced phenylacetylglutamine biosynthesis in a man with partial ornithine transcarbamylase (OTC) deficiency has a dual effect; it provides an additional vehicle for waste nitrogen excretion, and in the process it suppresses the patient"s residual urea N synthesis, which then may be available for N homeostasis if the need arises.	4-phenylbutyric acid	33-54	ornithine transcarbamylase	Homo sapiens	120-146	
8412748-1	1993	We evaluated the hypothesis that sodium phenylbutyrate-induced phenylacetylglutamine biosynthesis in a man with partial ornithine transcarbamylase (OTC) deficiency has a dual effect; it provides an additional vehicle for waste nitrogen excretion, and in the process it suppresses the patient"s residual urea N synthesis, which then may be available for N homeostasis if the need arises.	4-phenylbutyric acid	33-54	ornithine transcarbamylase	Homo sapiens	148-151	
22245901-3	2012	We investigated the effects of 4-phenylbutyrate (4PBA), a drug used to treat ornithine transcarbamylase deficiency (OTCD), on the cell surface expression and transport function of MRP2/Mrp2 and serum T-Bil concentration.	4-phenylbutyric acid	31-47	ornithine transcarbamylase	Homo sapiens	77-103	
35045794-4	2022	4-Phenylbutyrate (4-PBA), a drug used to treat ornithine transcarbamylase deficiency (DILI), is reported to alleviate RFP-induced liver cell injury.	4-phenylbutyric acid	0-16	ornithine transcarbamylase	Homo sapiens	47-73	
35045794-4	2022	4-Phenylbutyrate (4-PBA), a drug used to treat ornithine transcarbamylase deficiency (DILI), is reported to alleviate RFP-induced liver cell injury.	4-phenylbutyric acid	18-23	ornithine transcarbamylase	Homo sapiens	47-73	
26841694-2	2016	4-Phenylbutyrate (4 PB), a drug used to treat ornithine transcarbamylase deficiency, has been found to increase the hepatocanalicular expression of bile salt export pump.	4-phenylbutyric acid	0-16	ornithine transcarbamylase	Homo sapiens	46-72	
22262466-4	2012	We have shown previously that 4-phenylbutyrate (4PBA), a drug used for ornithine transcarbamylase deficiency (OTCD), inhibited internalization and subsequent degradation of cell-surface-resident BSEP.	4-phenylbutyric acid	30-46	ornithine transcarbamylase	Homo sapiens	71-97	
22245901-3	2012	We investigated the effects of 4-phenylbutyrate (4PBA), a drug used to treat ornithine transcarbamylase deficiency (OTCD), on the cell surface expression and transport function of MRP2/Mrp2 and serum T-Bil concentration.	4-phenylbutyric acid	49-53	ornithine transcarbamylase	Homo sapiens	77-103	
11286510-0	2001	Long-term treatment with sodium phenylbutyrate in ornithine transcarbamylase-deficient patients.	4-phenylbutyric acid	25-46	ornithine transcarbamylase	Homo sapiens	50-76	
23430866-5	2012	Our patient, now aged 5 years, has remained in excellent health with normal growth and development on fasting avoidance, a modified vegan diet, and sodium phenylbutyrate.These five cases demonstrate that generalized liver dysfunction/failure is a potential serious complication of OTC deficiency, although not a common one, and suggests that an ALT and PT should be obtained in OTC patients during episodes of hyperammonemia.	4-phenylbutyric acid	148-169	ornithine transcarbamylase	Homo sapiens	281-284	
11148526-1	2001	We describe a male patient with a Y202H ornithine transcarbamylase deficiency gene mutation who had pancreatitis while taking a low-protein diet, citrulline, and sodium phenylbutyrate.	4-phenylbutyric acid	162-183	ornithine transcarbamylase	Homo sapiens	40-66